Kropotova Alexandra
Visual SEC Form 4 history across 1 companies, 2 transactions and 2 filings.
Open-market buy performance
90-day forward return on this insider's open-market purchases
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Net value flow
Buys minus sells
Transaction texture
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
No latest transaction fact is available.
No open-market insider purchase is available.
No open-market insider sale is available.
Associated companies
Visual map of known reporting history
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #225637 | SABS | Kropotova Alexandra | CMO | withholding | 473 | — | F | 09/18 | 09/17 |
| #49134 | SABS | Kropotova Alexandra | CMO | grant | 2.40M | $0 | A | 02/05 | 02/03 |
Kropotova Alexandra Insider Activity FAQ
SEC Form 4 context
Who is Kropotova Alexandra?
Kropotova Alexandra is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001825323.
Which companies has Kropotova Alexandra reported transactions for?
SAB Biotherapeutics, Inc.
When was Kropotova Alexandra's latest insider buy?
No open-market insider purchase is available for this period.
When was Kropotova Alexandra's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.